Transient gene editing of the herpes simplex virus type 1 using mRNA-based CRISPR was shown for the first time to be effective against herpetic stromal keratitis in mice and blocked HSV-1 replication in human corneas, Chinese researchers reported in the January 11, 2021, online edition of Nature Biotechnology.